New cancer drug candidate T-1101 enters first human tests
Disease control
Completed
This early-stage trial tests a new oral drug called T-1101 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find the safest dose and understand how the body processes the drug. Researchers will also look for early signs of…
Phase: PHASE1 • Sponsor: Taivex Therapeutics Corporation • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC